- Lifecore Biomedical has signed an agreement with a global pharmaceutical company to provide technical transfer services for a commercially marketed injectable drug product.
- The program is Lifecore’s seventh late-stage commercial program and 11th pipeline addition in 2026, with commercial revenues expected to begin in 2028.
Lifecore Biomedical, Inc., an injectables contract development and manufacturing organization (CDMO), has signed an agreement with a global pharmaceutical company to transfer a commercially marketed injectable drug product into its pipeline. Under the agreement, Lifecore will provide technical transfer services to support commercial production of the product.
The agreement adds Lifecore’s seventh late-stage commercial program and its 11th pipeline program in 2026. The company said the program is expected to generate commercial revenues in 2028. Financial terms of the agreement were not disclosed in the press release.
The injectable product has a unique formulation and manufacturing complexity, according to Lifecore. The company said the program aligns with its technical expertise in high-viscosity and complex products. The technical transfer work will support the transition of the product into Lifecore’s commercial manufacturing activities.
With the addition of the program, Lifecore said its late-stage pipeline now contains 13 programs with the potential to generate commercial revenues by the end of 2028. The company also said the agreement expands its customer base through a new relationship with a global pharmaceutical company.
“A critical component of our growth strategy is our revamped commercial approach, focused on adding high-impact programs to our development pipeline. The addition of this new program provides clear evidence that this strategy is working.”
Paul Josephs, chief executive officer of Lifecore
